Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioVie Inc. (OTC: BIVI).

Full DD Report for BIVI

You must become a subscriber to view this report.


Recent News from (OTC: BIVI)

BioVie Inc. (OTCQB:BIVI) Attains Milestone
BEVERLY, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it has achieved 50% enrollment of the patients in its open-label Phase ...
Source: GlobeNewswire
Date: April, 09 2018 07:00
BioVie to Present at The MicroCap Conference in New York on April 9th
BEVERLY, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it will participate in The MicroCap Conference taking place in April in...
Source: GlobeNewswire
Date: March, 22 2018 07:00
BioVie Responds to Japan Patent Office and Comments on Recent Stock Price Decline
BEVERLY, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it submitted a response to questions raised by the Japanese Patent Offi...
Source: GlobeNewswire
Date: March, 07 2018 07:00
Stocks To Watch: Digging For Gems In The Shakeout
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Are you not entertained? The broad-based selling in equities in the U.S. and across...
Source: SeekingAlpha
Date: February, 10 2018 08:37
BioVie reviews key accomplishments in 2017 and updates on Phase 2a clinical trial progress
BioVie ( OTCQB:BIVI ) reviews key milestones achieved in 2017 and provides a general update on the progress of its mid-stage (Phase 2a) clinical trial of BIV201 in refractory ascites patients. More news on: BioVie Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: January, 16 2018 08:07
BioVie Reviews Key Accomplishments in 2017 and Updates on Phase 2a Clinical Trial Progress
BEVERLY, MA --(Marketwired - January 16, 2018) - BioVie Inc. (OTCQB: BIVI) , a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, today reviewed key milestones achieved over the past year and provided a general update on...
Source: Marketwired
Date: January, 16 2018 07:00
BioVie receives Fast Track Designation for BIV201 for the treatment of refractory ascites
BioVie ( OTCQB:BIVI ) announces that the FDA has granted Fast Track designation for BIV201 (continuous infusion terlipressin), the Company's Orphan drug candidate. More news on: BioVie Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: December, 11 2017 08:27
BioVie Receives FDA Fast Track Designation for BIV201 for the Treatment of Refractory Ascites Due to Advanced Liver Cirrhosis
BEVERLY, MA --(Marketwired - December 11, 2017) - BioVie Inc. (OTCQB: BIVI) , a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that the US Food and Drug Administration (FDA) has granted Fast Track de...
Source: Marketwired
Date: December, 11 2017 07:00
BioVie Announces Second Patient Dosed with BIV201 in Phase 2a Clinical Trial; First Patient Completes 28-day Treatment Regimen
BEVERLY, MA --(Marketwired - November 08, 2017) - BioVie Inc. (OTCQB: BIVI) , a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, reported today that a second patient has been dosed with the Orphan drug cand...
Source: Marketwired
Date: November, 08 2017 07:00
Accomplished BioPharma Executive Mina Sooch Joins BioVie Board of Directors and Purchases Company Stock
BEVERLY, MA --(Marketwired - November 02, 2017) - BioVie Inc. (OTCQB: BIVI) , a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today welcomed Mina Sooch, a highly seasoned biopharma industry executive, t...
Source: Marketwired
Date: November, 02 2017 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-110.040.0390.040.036234,916
2018-12-100.04990.04950.04990.049529,500
2018-12-070.04010.04750.04750.04113,000
2018-12-060.04110.05490.05490.04170,318
2018-12-05N/A0.041N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0625,00070,31835.5528Short
2018-11-3011,25082,45013.6446Cover
2018-11-2952,300125,60041.6401Short
2018-11-2894,100221,25042.5311Short
2018-11-2710,90010,900100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BIVI.


About BioVie Inc. (OTC: BIVI)

Logo for BioVie Inc. (OTC: BIVI)

BioVie Inc. is a clinical stage company pursuing the discovery, development, and commercialization of innovative drug therapies in liver disease. The Company is focused on commercializing BIV , a novel approach to the treatment of ascites due to chronic liver cirrhosis. Liver cirrhosis claims approximately , American lives each year. The FDA has never approved any drugs specifically for treating ascites and there is a substantial unmet medical need. The Company s new drug candidate BIV has Orphan Drug designation and is patented in the US. In early , the Company s investigational new drug IND application was cleared by the FDA to begin a Phase a clinical trial. This patient trial is being conducted at the McGuire Research Institute in Richmond, VA. As of year end , refractory ascites patients had been treated with BIV .

 

Contact Information

 

 

Current Management

  • Jonathan Adams / CEO, CFO
  • Jonathan Adams / Chairman
  • Cuong Do /
  • James Lang /

Current Share Structure

  • Market Cap: $5,791,415 - 03/09/2018
  • Authorized: 300,000,000 - 02/28/2018
  • Issue and Outstanding: 97,334,699 - 02/28/2018

 


Recent Filings from (OTC: BIVI)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 08 2017
OTCQB Certification - BioVie Certification Nov 7 2017
Filing Type: OTCQB Certification - BioVie Certification Nov 7 2017Filing Source: OTC Markets
Filing Date: November, 07 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 07 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 30 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 28 2017

 

 


Daily Technical Chart for (OTC: BIVI)

Daily Technical Chart for (OTC: BIVI)


Stay tuned for daily updates and more on (OTC: BIVI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BIVI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIVI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BIVI and does not buy, sell, or trade any shares of BIVI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/